A Preventive Option That Doubles as an Abortive

Most migraine medications do one job. Triptans, NSAIDs, and gepants like ubrogepant stop an attack once it starts. Beta-blockers, topiramate, amitriptyline, and the anti-CGRP monoclonal antibodies work in the background to make attacks less frequent. Rimegepant is unusual because it does both. The same 75 mg tablet that can abort an attack can also be taken every other day to prevent them.

That dual role matters for real people. If you are the kind of person who has tried five or six preventives and watched each one fizzle out, a treatment that pulls double duty is worth understanding well. A new real-world study out of Spain, published July 2026 in Cephalalgia, followed 150 people with hard-to-treat migraine who started rimegepant for prevention, and the results give us a clearer picture of who benefits, how much, and when in the treatment course it is best used.

What Rimegepant Actually Is

Rimegepant (brand name Nurtec ODT in the US, Vydura in Europe) belongs to a class called gepants, which are small-molecule blockers of the calcitonin gene-related peptide (CGRP) receptor. It comes as an orally disintegrating tablet that dissolves on the tongue, so it does not need water and is easier to take when nausea makes swallowing pills unpleasant.

It is the first drug approved for both the acute treatment of migraine attacks and the preventive treatment of episodic migraine. For acute use, you take one 75 mg tablet when an attack hits. For prevention, you take one 75 mg tablet every other day. This is a real practical advantage: someone using it every other day for prevention can, on the off days, take an extra dose to treat a breakthrough attack, though the label caps total use at one dose in any 24-hour period and 18 doses per month.

How It Works, in Plain Terms

CGRP is a small signaling molecule released from the trigeminal nerve, the sensory network that carries pain from the face and head. During a migraine attack, CGRP levels rise. It dilates blood vessels around the brain's lining, ramps up inflammation in the surrounding tissue, and turns up the volume on pain-signaling neurons, a process called sensitization. Over decades of work, CGRP went from an interesting laboratory finding to the single best-validated molecular target in migraine, which is why blocking it has been so productive.

Rimegepant sits on the CGRP receptor and stops CGRP from binding. When taken during an attack, it interrupts the pain cascade already in motion. When taken regularly for prevention, the thinking is that it keeps a lid on the trigeminal system's excitability so attacks are less likely to get started in the first place. The same mechanism explains both jobs, which is unusual and useful.

The GEMA Study: Real-World, Not a Clinical Trial

The evidence that first got rimegepant approved for prevention came from a tightly controlled randomized trial. That is the gold standard, but it enrolls carefully selected patients who often look nothing like the people filling headache clinic waiting rooms. The new study, part of the GEMA (GEpants in MigrAine) Project, was built to answer a different question: how does rimegepant perform in ordinary practice, in the messy, treatment-resistant population that clinicians actually see?

According to PubMed, researchers ran a prospective, multicenter, real-world cohort study across nine tertiary headache units in Spain. Adults starting rimegepant for prevention were enrolled one after another and followed for up to six months. The main outcome was the change in monthly headache days at three months, with monthly migraine days, response rates, predictors of response, and tolerability tracked alongside. They also captured patient-reported measures for headache impact (HIT-6), anxiety and depression (HADS), and insomnia.

The makeup of this group is the whole point. A median of six failed preventives is a lot. These are people for whom the standard playbook has largely run out, which makes any meaningful improvement clinically important and worth paying attention to.

What They Found

At three months, the median number of monthly headache days dropped from 12 to 7.5, and monthly migraine days fell from 10 to 6. Both changes were statistically significant, and headache impact on daily life (measured by HIT-6) improved meaningfully too. For a group this treatment-resistant, cutting headache days by roughly a third is a real result.

Two things stand out. First, response grew with time. Among the 64 people followed to six months, the share reaching a 50% reduction climbed from about a third to roughly half, which suggests rimegepant is worth giving a fair trial of a few months before judging it. Second, the people who responded also reported greater improvements in anxiety and depressive symptoms. That is not proof the drug treats mood directly, but it fits what we see clinically: when the attacks ease, the mental load of living with migraine eases too.

The Honest Caveat: It Works Less Well After Anti-CGRP Antibodies

This is the part that changes how the drug should be used. The study found that certain factors independently predicted a poorer response: ongoing medication overuse, chronic migraine, and prior exposure to anti-CGRP monoclonal antibodies and to onabotulinumtoxinA (Botox). Most striking, response declined as prior anti-CGRP antibody exposure increased. The more CGRP-targeting antibodies someone had already failed, the less likely rimegepant was to help, though a meaningful share still got benefit.

This makes biological sense. Rimegepant and the antibodies both act on the CGRP pathway. If your migraine has already proven resistant to blocking CGRP one way, blocking it another way is less likely to be the answer. It does not mean rimegepant is useless after antibody failure, and the data show some people still respond, but the odds are lower.

"The most useful takeaway here is not just that rimegepant works. It is that where you place it in the sequence matters. Reaching for it earlier, before a person has cycled through multiple CGRP antibodies, appears to give the best shot at a real response." - Cerebral Torque

The authors reached the same conclusion: earlier use of rimegepant in the treatment course may be associated with greater benefit. For patients, that is a concrete talking point for your next neurology visit. If you and your clinician are weighing where a gepant fits, "sooner rather than after everything else" is a defensible position grounded in this data.

Dosing, Timing, and How the Options Compare

Rimegepant's preventive dose is one 75 mg orally disintegrating tablet every other day. Its acute dose is one 75 mg tablet at the onset of an attack. The table below puts it alongside the other main preventive routes so you can see where the evidence is strong and where it is thinner. Evidence grades reflect the strength and directness of the data, not a ranking of how well any drug will work for one individual.

Evidence key: Strong (RCT) = supported by randomized controlled trials. Moderate / real-world / established = supported by observational cohorts or long clinical use rather than head-to-head trials. Limited / associational = suggestive only, not a basis for prescribing decisions.

Safety and Who Should Think Twice

Tolerability was one of the brighter parts of the GEMA data. Adverse events were mostly mild. Nausea was the most common at 13%, followed by constipation at 8%, and only 7% of people stopped the drug by three months, with nausea being the usual reason. That fits rimegepant's broader track record, where side-effect rates in the pivotal trials were close to placebo.

A few cautions are worth naming plainly. Gepants have not been studied in pregnancy and are generally avoided there, which is relevant given how many people with migraine are of reproductive age. People with significant liver impairment need dose consideration, and rimegepant interacts with strong inhibitors and inducers of the CYP3A4 enzyme (for example certain antifungals, some antibiotics, and some seizure medications), so a full medication review is sensible before starting. Unlike triptans, gepants do not constrict blood vessels, which is actually a point in their favor for people with cardiovascular risk who cannot take triptans. As always, these are conversations to have with your own prescriber, not rules to apply yourself.

Where Rimegepant Fits in the Bigger Picture

Current expert guidance has already moved CGRP-targeting treatments, including the gepants, into first-line territory for prevention. The American Headache Society's position is that these therapies no longer need to be reserved until older preventives have failed, because their evidence base and tolerability match or exceed what came before. The GEMA study slots neatly into that shift by showing rimegepant earning its keep even in people the older drugs could not help.

Practical Guidance for Patients

If rimegepant comes up as an option, a few things will help you get the most out of a trial and have a productive conversation with your clinician.

Conclusions

Rimegepant is one of the more flexible tools in migraine care: a single CGRP receptor blocker that can both stop an attack and, taken every other day, prevent them. This new real-world study strengthens the case that it works in ordinary practice, not just in trials, and that it can help even in people who have exhausted much of the standard preventive menu. Roughly a third responded by three months and nearly half by six, with mild side effects and low dropout.

The most actionable insight is about timing. Because rimegepant works less well the more anti-CGRP antibodies someone has already failed, the data point toward using it earlier in the treatment course rather than holding it in reserve. For people living with migraine, that is a specific, evidence-backed question to raise with a clinician. For clinicians, it is a nudge to think about sequence, not just whether a drug is on the list.